Search

Dr. Stephen Vaughan (University of Calgary) successfully treated 76-year-old Boyd English's decade-long antibiotic-resistant hip infection using phage therapy. This is the first PJI phage treatment in Western Canada.

In mouse models of acute Pseudomonas aeruginosa pneumonia, depleting alveolar macrophages shortened the survival of adult male mice without raising lung bacterial load, yet lung P. aeruginosa levels were significantly lower in macrophage-de

Phagos, a French phage biotech company, is hiring for multiple roles!

Phagos, a French phage biotech company, is hiring for multiple roles!

Tolka AI Therapeutics in South Florida is hiring a Research Associate Intern, to study phage therapy against antibiotic-resistant superbugs through environmental sample collection and discovery pipeline optimization.

Tolka AI Therapeutics in South Florida is hiring a Research Associate Intern, to study phage therapy against antibiotic-resistant superbugs through environmental sample collection and discovery pipeline optimization.

Tolka AI Therapeutics in South Florida is hiring a Research Associate Intern, to study phage therapy against antibiotic-resistant superbugs through environmental sample collection and discovery pipeline optimization.

The Global Clinical Phage Rounds (GCPR) is an ongoing forum for discussing phage therapy cases and advances among clinicians and scientists. The organizers (Greg German, Gina Suh, Jon Iredell and colleagues) are excited to announce a speci

You’re invited to submit an abstract to the inaugural Conference on Bacteriophages: Biology, Dynamics, and Therapeutics, chaired by Graham Hatfull (University of Pittsburgh) and Robert (Chip) Schooley (UCSD). Topics range from phage struct

Tolka AI Therapeutics has announced expanded access to patient-tailored phage therapy for M. abscessus infections. They're screening patients at five institutions for compassionate use where standard antibiotics have failed.

Ruby Darwin, a PhD student in the University of Liverpool's Department of Infection Biology and Microbiomes, attended the two-day Targeting Phage Therapy 2025 conference virtually with IVES small grant funds. She highlights a first clinical

You’re invited to submit an abstract to the inaugural Conference on Bacteriophages: Biology, Dynamics, and Therapeutics, chaired by Graham Hatfull (University of Pittsburgh) and Robert (Chip) Schooley (UCSD). Topics range from phage struct

Tolka AI Therapeutics has announced expanded access to patient-tailored phage therapy for M. abscessus infections. They're screening patients at five institutions for compassionate use where standard antibiotics have failed.

Ortal Yerushalmy (Hebrew University of Jerusalem) and colleagues published a new paper on phage susceptibility diversity in CF Burkholderia isolates, showing mixed populations of phage-sensitive and phage-resistant Burkholderia in 75% of CF

SNIPR Biome announced on June 12, 2025 that the first patient has been dosed in its Phase 1b study of SNIPR001, an orally administered CRISPR-armed phage therapeutic that targets E. coli in the gut, in hematological cancer patients undergoi

A team of authors from Israel and Portugal, including researchers from the Hadassah Medical Organization, tested the bacteriophage mixture TP-102 on 19 diabetic patients with infected and non-infected foot ulcers. TP-102 was safe and well t

You’re invited to submit an abstract to the inaugural Conference on Bacteriophages: Biology, Dynamics, and Therapeutics, chaired by Graham Hatfull (University of Pittsburgh) and Robert (Chip) Schooley (UCSD). Topics range from phage struct

The World Health Organization published a new report on phage therapy evidence, showing phages can enhance antibiotic treatments against resistant bacteria as part of a One Health approach.

Tolka AI Therapeutics has announced expanded access to patient-tailored phage therapy for M. abscessus infections. They're screening patients at five institutions for compassionate use where standard antibiotics have failed.

A much awaited regulatory guidance document! The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced new guidance for developing phage therapies in the UK.